Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors.
Tamaoki
T
T
D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D001358:Avian Sarcoma Viruses / Q000235:genetics; D001921:Brain / Q000201:enzymology; D002417:Cattle; D002460:Cell Line; D002642:Chick Embryo; D015394:Molecular Structure; D009206:Myocardium / Q000201:enzymology; D009281:Naphthalenes; D015688:Oncogene Protein pp60(v-src) / Q000037:antagonists & inhibitors*; D011083:Polycyclic Compounds / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000302:isolation & purification; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000302:isolation & purification; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000302:isolation & purification; D051381:Rats; D019311:Staurosporine / Q000031:analogs & derivatives; D013329:Structure-Activity Relationship
D000470:Alkaloids; D009281:Naphthalenes; D011083:Polycyclic Compounds; D047428:Protein Kinase Inhibitors; C054852:7-hydroxystaurosporine; D011494:Protein Kinases; D011505:Protein-Tyrosine Kinases; D015688:Oncogene Protein pp60(v-src); D011493:Protein Kinase C; D019311:Staurosporine; C058819:calphostin C